Skip to main content
SpringerLink
Log in

Sulphasalazine: A Review of 40 Years’ Experience

  • Published:
Drugs Aims and scope Submit manuscript

Summary

Sulphasalazine, devised by Dr Nana Svartz for the treatment of ‘infective polyarthritis’,. has been used in the treatment of inflammatory bowel disease for more than 40 years. Many controlled trials have shown that sulphasalazine 4g daily will induce remissions in between one-half and three-quarters of patients with acute attacks of ulcerative colitis. When given in a dosage of 2g daily it will prevent relapses in quiescent colitis. Relapses are 5 times more likely in untreated patients. It is less effective in Crohn’s disease, where it exerts only a transient benefit in patients with active colonic disease and fails to prevent relapse or recurrence.

Sulphasalazine is absorbed from the small intestine, re-excreted in bile and carried to the colon, where its azo bond is split by bacteria to release sulphapyridine, which is absorbed and is responsible for most of the drug’s side effects, and 5-aminosalicylic acid, which is the active therapeutic moiety of the drug and exerts a beneficial topical action on the colonic mucosa.

Side effects are common but are mainly reversible and not serious. Those related to high concentrations of sulphapyridine and to poor acetylation of the drug include gastrointestinal intolerance, malaise, headache, arthralgia, drug fever, effects on red blood cells and reversible male infertility. More serious, idiosyncratic side effects are skin rashes, leucopenia and agranulocytosis. Rarely, neurotoxicity, hepatotoxicity, polyarteritis, pulmonary fibrosis, a lupus-like syndrome and haemorrhagic colitis are produced. It is possible to desensitise most patients with drug-induced skin rashes.

A number of less toxic alternatives to sulphasalazine have been devised and are undergoing trial. They either convey 5-aminosalicylic acid in a coated tablet to the colon or, when conjugated to a non-toxic carrier, release 5-aminosalicylic acid by bacterial cleavage there.

Sulphasalazine remains a most useful drug in the treatment of inflammatory bowel disease after 40 years of use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Anthonisen PA, Bárány F, Folkenberg O, Holtz A, Jamum S, et al. The clinical effect of salazosulphapyridine (salazopyrin) in Crohn’s disease. Scandinavian Journal of Gastroenterology 9: 549–554, 1974

    PubMed  CAS  Google Scholar 

  • Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2: 892–895, 1977

    Article  PubMed  CAS  Google Scholar 

  • Azad Khan AK, Howes DT, Piris J, Truelove SC. Optimum dose of sulphasalazine for maintenance treatment of ulcerative colitis. Gut 21: 232–240, 1980

    Article  PubMed  CAS  Google Scholar 

  • Baron JH, Connell AM, Lennard-Jones JE, Jones F. Avery. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet 1: 1094–1096, 1962

    Article  PubMed  CAS  Google Scholar 

  • Bergman L, Krause U. Post-operative treatment with corticosteroids and salicylazosulphapyridine (salazopyrin) after radical resection for Crohn’s disease. Scandinavian Journal of Gastroenterology 11: 651–656, 1976

    PubMed  CAS  Google Scholar 

  • Birnie GG, McLeod TIF, Watkinson G. Incidence of sulphasalazine-induced male infertility. Gut 22: 452–455, 1981

    Article  PubMed  CAS  Google Scholar 

  • Block MB, Genant HK, Kirsner JB. Pancreatitis as an adverse reaction to salicylazosulphapyridine. New England Journal of Medicine 282: 380–382, 1970

    Article  PubMed  CAS  Google Scholar 

  • Callen JP, Soderstrom RM. Granulomatous hepatitis associated with salicylazosulfapyridine therapy. Southern Medical Journal 71: 1159–1160, 1978

    Article  PubMed  CAS  Google Scholar 

  • Das KM, Eastwood MA, McManus JPA, Sircus W. The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the progress of the disease studied in outpatients. II. The relationship between metabolites and the progress of the disease studied in outpatients. Gut 14: 631–641, 1973a

    Article  PubMed  CAS  Google Scholar 

  • Das KM, Eastwood MA, McManus JPA, Sircus W. The metabolism of salicylazosulphapyridine therapy and relation with drug metabolism and acetylator phenotype. New England Journal of Medicine 289: 491–495, 1973b

    Article  PubMed  CAS  Google Scholar 

  • Dew MJ, Hughes PJ, Harries AD, Williams G, Evans BK, Rhodes J. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis: a controlled trial. Gut 23: A392, 1982

    Google Scholar 

  • Dew MJ, Harries AD, Evans N, Rhodes J. Maintenance of remission in ulcerative colitis with an oral preparation of 5-aminosalicylic acid in high doses. Gut 24: A983, 1983

    Google Scholar 

  • Dick AP, Grayson MJ, Carpenter RG, Petrie A. Controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut 5: 437–442, 1964

    Article  PubMed  CAS  Google Scholar 

  • Dissanayake MW, Truelove SC. A controlled therapeutic trial of long term maintenance treatment in ulcerative colitis with sulphasalazine (salazopyrin). Gut 14: 923–926, 1973

    Article  PubMed  CAS  Google Scholar 

  • Franklin JL, Rosenberg IM. Impaired folic acid absorption in inflammatory bowel disease: effects of salicylazosulfapyridine (Azulfidine). Gastroenterology 64: 517–525, 1973

    PubMed  CAS  Google Scholar 

  • Frühmorgen P, Demling L. On the efficacy of ready made up commercially available salicylazosulphapyridine enemas in the treatment of proctitis, proctosigmoiditis and ulcerative colitis involving rectum, sigmoid and descending colon. Hepato-Gastroenterology 27: 473–476, 1980

    PubMed  Google Scholar 

  • Goldman P, Peppercorn MA. Drug therapy. Sulphasalazine. New England Journal of Medicine 293: 20–23, 1975

    Article  PubMed  CAS  Google Scholar 

  • Griffiths ID, Kane SP. Sulphasalazine-induced lupus syndrome in ulcerative colitis. British Medical Journal 2: 1188–1189, 1977

    Article  PubMed  CAS  Google Scholar 

  • Halsted CH, Gandhi G, Tamura T. Sulphasalazine inhibits absorption of folates in ulcerative colitis. New England Journal of Medicine 305: 1513–1517, 1981

    Article  PubMed  CAS  Google Scholar 

  • Hanke P, Sculz U. Ersahrungen mit der rectalen Azulfidine-therapie. Zeitschrift für die Gesamte Innere Medizin 28:Supplement 292/3, 1971

    Google Scholar 

  • Holdsworth CD. Sulphasalazine desensitisation. British Medical Journal 282: 110, 1981

    Article  PubMed  CAS  Google Scholar 

  • Ireland A, Selby WS, Barr GD, Mason CH, Jewell DP. Azodisalicylate for the treatment of active ulcerative colitis (uc).Gut 26: A1157, 1985

    Google Scholar 

  • Jamshidi K, Arlanda T, Garcia MC, Windschitl HW, Swain WR. Azufidine agranulocytosis with bone marrow megakaryocytosis, histiocytosis and plasmacytosis. Minnesota Medicine 55: 545–548, 1972

    PubMed  CAS  Google Scholar 

  • Juhl RP, Summers RW, Guillony JK. Effect of sulphasalazine in digoxin bioavailability. Clinical Pharmacology and Therapeutics 20: 387–394, 1976

    PubMed  CAS  Google Scholar 

  • Kirsher JB, Goodman MJ. The medical treatment of inflammatory bowel disease. In Kirsher JB & Shorter RG (Eds) Inflammatory Bowel Disease, pp. 419–422, Lea & Febinger, Philadelphia, 1980

    Google Scholar 

  • Korelitz BI, Present DH, Rubin PH, Fuchios SE. Desensitization to sulfasalazine after hypersensitivity reactions in patients with inflammatory bowel disease. Journal of Clinical Gastroenterology 6: 27–31, 1984

    Article  PubMed  CAS  Google Scholar 

  • Lennard-Jones JE. Sulphasalazine in asymptomatic Crohn’s disease. A multicentre trial. Gut 18: 69–72, 1977

    Article  PubMed  CAS  Google Scholar 

  • Lennard-Jones JE, Longmore AJ, Newell AC, Wilson CWE, Avery JF. An assessment of prednisolone, salazopyrine and topical hydrocortisone hemisuccinate used as outpatient treatment for ulcerative colitis. Gut 1: 217–222, 1960

    Article  PubMed  CAS  Google Scholar 

  • Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, et al. European Co-operative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology 86: 249–266, 1984

    PubMed  CAS  Google Scholar 

  • Misiewicz JJ, Lennard-Jones JE, Connell AM, Baron JH, Jones F. Avery. Control trial of sulphasalazine in maintenance treatment for ulcerative colitis. Lancet 1: 185–188, 1965

    Article  Google Scholar 

  • Moertal CG, Bargen JA. A critical analysis of the use of salicylazosulphapyridine in chronic ulcerative colitis. Annals of Internal Medicine 51: 879–889, 1959

    Google Scholar 

  • Morrison LM. Response of ulcerative colitis with salicylazosulphapyridine. Journal of the American Medical Association 151: 366–368, 1953

    PubMed  CAS  Google Scholar 

  • Palmer KR, Goepal JR, Holdsworth CD. Sulphasalazine retention enemas in ulcerative colitis: a double blind trial. British Medical Journal 282: 1571–1573, 1981

    Article  PubMed  CAS  Google Scholar 

  • Pounder RE, Craven ER, Henthorn JS, Bannatyne JM. Red cell abnormalities associated with sulphasalazine maintenance therapy for ulcerative colitis. Gut 16: 181–185, 1975

    Article  PubMed  CAS  Google Scholar 

  • Riis P, Anthonisen P, Wurf HR, Folkenborg D, Bonnevie O, Binder V. The prophylactic effect of sulphapyridine in ulcerative colitis during long term treatment. Scandinavian Journal of Gastroenterology 8: 71–74, 1973

    PubMed  CAS  Google Scholar 

  • Schwartz AG, Targan SR, Saxon A, Weinstein WM. Sulfasalazine-induced exacerbation of ulcerative colitis. New England Journal of Medicine 306: 409–412, 1982

    Article  PubMed  CAS  Google Scholar 

  • Singleton JW, Summers RW, Kern Jr F, Becktel JM, Best WR. A trial of sulfasalazine as adjunctive therapy in Crohn’s disease. Gastroenterology 77(4 Pt 2): 887–897, 1979

    PubMed  CAS  Google Scholar 

  • Spriggs AI, Smith RS, Griffith H, Truelove SC. Heinz body anaemia due to salicylazo-sulphapyridine. Lancet 1: 1039–1042, 1958

    Article  PubMed  CAS  Google Scholar 

  • Summers RW, Switz DM, Sessions JT, Becktel JM, et al. National Cooperative Crohn’s disease study: results of drug treatment. Gastroenterology 77: 847–869, 1979

    PubMed  CAS  Google Scholar 

  • Svartz N. Salazopyrin, a new sulfanilamide preparation. Acta Medica Scandinavica 110: 577–598, 1942

    Article  Google Scholar 

  • Swinson CM, Perry J, Lumb M, Levi AJ. Role of sulphasalazine in aetiology of folate deficiency in ulcerative colitis. Gut 22: 456–461, 1981

    Article  PubMed  CAS  Google Scholar 

  • Toovey S, Hudson E, Hendry WF, Levi AJ. Sulphasalazine and male infertility: reversibility and possible mechanism. Gut 22: 445–451, 1981

    Article  PubMed  CAS  Google Scholar 

  • Toth A. Reversible toxic effect of salicylazosulphapyridine on semen quality. Fertility and Sterility 31: 538–540, 1979

    PubMed  CAS  Google Scholar 

  • Truelove SC, Watkinson G, Draper G. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis. British Medical Journal 2: 1708–1711, 1962

    Article  PubMed  CAS  Google Scholar 

  • Tydd TF, Dyer NH. Sulphasalazine lung. Medical Journal of Australia 1: 570–573, 1976

    PubMed  CAS  Google Scholar 

  • Van Hees PAM, Van Lien HJJ, Van Eltren PH, Driessen WMM, Van Hogesand RA, et al. Effect of sulphasalazine in patients with active Crohn’s disease. A controlled double-blind study. Gut 22: 404–409, 1981

    Article  PubMed  Google Scholar 

  • Watkinson G. Medical management of ulcerative colitis. British Medical Journal 1: 147–149, 1961

    Article  PubMed  CAS  Google Scholar 

  • Watkinson G. The medical treatment of ulcerative colitis. Postgraduate Medical Journal 44: 696–707, 1968

    Article  PubMed  CAS  Google Scholar 

  • Wenckert A, Kristensen M, Eklund AE, Barany F, Jarnum S, et al. The long term prophylactic effect of salicylazosulphapyridine (salazopyrine) in primarily resected patients with Crohn’s disease. A controlled double blind trial. Scandinavian Journal of Gastroenterology 13: 161–167, 1978

    Article  PubMed  CAS  Google Scholar 

  • Werlin SL, Grand RJ. Bloody diarrhoea — a new complication of sulfasalazine. Journal of Pediatrics 92: 450–451, 1978

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Gardiner Institute, Western Infirmary, Glasgow, G11 6NT, Scotland

    Geoffrey Watkinson (Consultant Physician and Gastroenterologist)

Authors
  1. Geoffrey Watkinson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Watkinson, G. Sulphasalazine: A Review of 40 Years’ Experience. Drugs 32 (Suppl 1), 1–11 (1986). https://doi.org/10.2165/00003495-198600321-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-198600321-00003

Keywords

Search

Navigation